New Three-Drug cocktail takes on Hard-to-Treat myeloma
NCT ID NCT07348393
First seen Jan 17, 2026 · Last updated Jun 22, 2026 · Updated 21 times
Summary
This Phase 2 trial tests a new combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 70 adults with relapsed or refractory multiple myeloma who have already tried lenalidomide and an anti-CD38 antibody. The goal is to see if this combo can slow or stop the cancer from growing. Participants must have measurable disease and be in adequate health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Saint-Antoine Hospital
Paris, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mezigdomide, carfilzomib, and dexamethasone
What this could lead to
If successful, this combination could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is an early Phase 2 trial with only 70 participants, so results may not apply to everyone. The drug combination may cause side effects or not work as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.